Thrombocytopenia and megakaryopoiesis

Thrombocytopenia is defined by a platelet count ≤ 150 G/L. Some patients have an acquired persistent isolated thrombocytopenia, with no evidence for increased platelet destruction or bone marrow defect when observed histologically. Their platelets count stays above 30G/L and they rarely require any treatment. They are classified as Chronic-Immune Thrombocytopenia (C-ITP) by exclusion of other diagnosis. We recently described that these patients have an intrinsic defect in platelet production, i.e. proplatelet formation, and thus a “hematological” disease, rather than an immune platelet destruction.

Preliminary results from our group are in favour of a deregulated intrinsic apoptotic pathway in the platelets from these patients, and we found an interesting candidate protein (under patent).

The PhD candidate will decipher the pathogenesis of this new form of acquired thrombocytopenia (which we call “hematological ITP”), by testing the role of the candidate protein we found, and validate whether it could be used as a biomarker that could be used in the clinic to easily diagnose this type of patients.

Principal investigator





Jean-François VIALLARD